The closing price of Accelerate Diagnostics Inc (NASDAQ: AXDX) was $0.99 for the day, down -1.98% from the previous closing price of $1.01. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 86531 shares were traded.
Ratios:
Our analysis of AXDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.86.
Craig Hallum Upgraded its Hold to Buy on August 07, 2020, while the target price for the stock was maintained at $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 26 ’24 when Patience David sold 350 shares for $0.96 per share. The transaction valued at 336 led to the insider holds 26,247 shares of the business.
Phillips Jack sold 494 shares of AXDX for $642 on Feb 01 ’24. The Chief Executive Officer now owns 76,707 shares after completing the transaction at $1.30 per share. On Dec 13 ’23, another insider, Phillips Jack, who serves as the Chief Executive Officer of the company, sold 739 shares for $4.39 each. As a result, the insider received 3,244 and left with 59,535 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXDX now has a Market Capitalization of 20.47M and an Enterprise Value of 35.89M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.67. Its current Enterprise Value per Revenue stands at 2.99 whereas that against EBITDA is -0.68.
Stock Price History:
The Beta on a monthly basis for AXDX is 0.52, which has changed by -85.86% over the last 52 weeks, in comparison to a change of 27.86% over the same period for the S&P500. Over the past 52 weeks, AXDX has reached a high of $11.90, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 1.1256, while the 200-Day Moving Average is calculated to be 4.7543.
Shares Statistics:
AXDX traded an average of 127.00K shares per day over the past three months and 71.98k shares per day over the past ten days. A total of 20.27M shares are outstanding, with a floating share count of 12.18M. Insiders hold about 39.92% of the company’s shares, while institutions hold 11.88% stake in the company. Shares short for AXDX as of Mar 15, 2024 were 287.62k with a Short Ratio of 2.26, compared to 347.32k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.42% and a Short% of Float of 1.65%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.62 for the current quarter, with a high estimate of -$0.62 and a low estimate of -$0.62, while EPS last year was -$1.4. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.54 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$4.63 and -$4.63 for the fiscal current year, implying an average EPS of -$4.63. EPS for the following year is -$2.03, with 1 analysts recommending between -$2.03 and -$2.03.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $3.79M to a low estimate of $3.1M. As of the current estimate, Accelerate Diagnostics Inc’s year-ago sales were $2.97M, an estimated increase of 16.10% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $4.14M, an increase of 47.20% over than the figure of $16.10% in the same quarter last year. There is a high estimate of $4.27M for the next quarter, whereas the lowest estimate is $4M.
A total of 2 analysts have provided revenue estimates for AXDX’s current fiscal year. The highest revenue estimate was $12.82M, while the lowest revenue estimate was $12.1M, resulting in an average revenue estimate of $12.46M. In the same quarter a year ago, actual revenue was $12.75M, down -2.30% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $18.76M in the next fiscal year. The high estimate is $19.02M and the low estimate is $18.5M. The average revenue growth estimate for next year is up 50.60% from the average revenue estimate for this year.
